TED STEWART, District Judge.
This matter is before the Court on Xymogen's Motion In Limine No. 3 to Exclude Expert Testimony Regarding Dr. Paul Abato's Alleged Reliance on Eurofins Report. For the following reasons, the Court denies the Motion.
On June 6, 2016, Plaintiffs Thorne Research, Inc.'s and Softgel Formulators, Inc.'s (collectively "Thorne") expert, Kent Rader, submitted a declaration to which a report from Eurofins Scientific Inc. Supplement Analysis Center (the "Report") was attached. The Report details chemical analyses performed on Xymogen's accused products.
On May 17, 2017, Thorne served Dr. Paul Abato's expert report, in which he explains the materials he considered in reaching his opinions regarding the contents of Xymogen's accused products.
In their Response, Thorne argues Dr. Abato should not be precluded from offering testimony that he relied on the Report in reaching his conclusions because Xymogen was put on notice that Dr. Abato did in fact rely on the Report. Thorne cites to two disclosures to support its argument. First, Dr. Abato's deposition transcript, wherein Xymogen asked him if "the [Report] analyze[d] the chemical composition of the accused products" and what the Report concluded about the products.
An expert report must contain "a complete statement of all opinions the witness will express and the basis and reasons for them [and] the facts or data considered by the witness in forming them."
There is no Rule 26 violation, so Rule 37(c) does not apply. But, even if there was a violation, it is harmless since the Court finds that the weight of the above-stated factors is in favor of allowing Dr. Abato to testify regarding the Report.
First, Thorne has shown sufficient evidence that Xymogen was on notice that Dr. Abato relied on the Report in reaching his conclusions. In fact, as referenced, Thorne questioned him in regard to the contents of the Report during his deposition. Therefore, the prejudice or surprise to Xymogen is minimal. Because there is minimal prejudice, the ability of Xymogen to cure the prejudice is irrelevant. Therefore, both the first and second factors weight in favor of allowing Dr. Abato to discuss the Report.
Third, the extent to which allowance of the disputed testimony will disrupt trial is minimal. Dr. Abato will simply discuss an additional document which supports his conclusions. Trial will not be interrupted in any meaningful way by this addition.
Finally, the record does not support that Thorne acted in bad faith. Thorne knew that Xymogen had knowledge of the Report as it was contained in the Docket, and further, because Xymogen asked Dr. Abato about the Report in his deposition.
Based on the above analysis, the Court finds allowing Dr. Abato to testify about the Report to be harmless and will deny Xymogen's Motion accordingly.
It is therefore
ORDERED that Defendant's Motion In Limine No. 3 to Exclude Expert Testimony Regarding Dr. Paul Abato's Alleged Reliance on Eurofins Report (Docket No. 278) is DENIED.